Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$103.68
+0.2%
$105.66
$89.67
$121.64
$180.36B0.745.68 million shs3.68 million shs
AstraZeneca PLC stock logo
AZN
AstraZeneca
$79.59
+0.1%
$75.46
$60.47
$80.86
$246.77B0.483.76 million shs2.06 million shs
Novartis AG stock logo
NVS
Novartis
$105.72
-0.3%
$99.84
$92.19
$108.78
$216.09B0.581.16 million shs2.57 million shs
Roche Holding AG stock logo
RHHBY
Roche
$34.67
+0.4%
$31.43
$29.20
$40.15
N/A0.442.49 million shs1.52 million shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+0.21%-3.63%-0.85%-10.23%+0.40%
AstraZeneca PLC stock logo
AZN
AstraZeneca
+0.08%-0.54%+3.40%+20.03%+9.37%
Novartis AG stock logo
NVS
Novartis
-0.28%+0.38%+2.42%+8.69%+6.06%
Roche Holding AG stock logo
RHHBY
Roche
+0.43%+3.34%+10.41%+6.22%-8.98%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9804 of 5 stars
3.44.04.24.52.82.52.5
AstraZeneca PLC stock logo
AZN
AstraZeneca
3.3913 of 5 stars
2.35.01.70.03.40.03.1
Novartis AG stock logo
NVS
Novartis
2.8318 of 5 stars
2.15.02.50.02.40.02.5
Roche Holding AG stock logo
RHHBY
Roche
1.126 of 5 stars
1.93.01.70.01.30.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.70
Moderate Buy$120.6416.35% Upside
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.67
Moderate Buy$88.0010.57% Upside
Novartis AG stock logo
NVS
Novartis
2.25
Hold$116.6710.35% Upside
Roche Holding AG stock logo
RHHBY
Roche
1.88
Reduce$40.0015.37% Upside

Current Analyst Ratings

Latest RHHBY, NVS, ABT, and AZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$125.00 ➝ $125.00
5/30/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$121.00
5/30/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$80.00 ➝ $85.00
5/30/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$97.00
5/30/2024
Novartis AG stock logo
NVS
Novartis
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$120.00
5/30/2024
Roche Holding AG stock logo
RHHBY
Roche
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell
5/22/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$128.00 ➝ $119.00
5/17/2024
Roche Holding AG stock logo
RHHBY
Roche
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
4/26/2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$80.00 ➝ $82.00
4/24/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$124.00
4/24/2024
Novartis AG stock logo
NVS
Novartis
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$114.00 ➝ $116.00
(Data available from 6/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$40.11B4.50$6.38 per share16.26$22.36 per share4.64
AstraZeneca PLC stock logo
AZN
AstraZeneca
$45.81B5.39$5.40 per share14.74$12.63 per share6.30
Novartis AG stock logo
NVS
Novartis
$45.44B4.76$11.08 per share9.54$22.87 per share4.62
Roche Holding AG stock logo
RHHBY
Roche
$65.37BN/A$3.12 per share11.11$4.91 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$5.72B$3.2132.3020.252.4913.96%20.18%10.60%7/18/2024 (Estimated)
AstraZeneca PLC stock logo
AZN
AstraZeneca
$5.96B$2.0439.0117.041.4313.30%30.42%11.62%7/26/2024 (Estimated)
Novartis AG stock logo
NVS
Novartis
$14.85B$7.4114.2712.921.6331.33%32.15%13.59%7/16/2024 (Estimated)
Roche Holding AG stock logo
RHHBY
Roche
$12.81BN/A0.0013.037.72N/AN/AN/A7/23/2024 (Estimated)

Latest RHHBY, NVS, ABT, and AZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/25/2024Q1 2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
$0.95$1.03+$0.08$1.36$11.92 billion$12.68 billion
4/23/2024Q1 2024
Novartis AG stock logo
NVS
Novartis
$1.73$1.80+$0.07$2.29$11.50 billion$11.83 billion
4/17/2024Q1 24
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$0.96$0.98+$0.02$1.26$9.88 billion$9.96 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.202.12%+12.31%68.54%53 Years
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.932.42%+1.18%94.61%N/A
Novartis AG stock logo
NVS
Novartis
$2.432.30%+4.26%32.79%N/A
Roche Holding AG stock logo
RHHBY
Roche
$0.852.45%N/AN/AN/A

Latest RHHBY, NVS, ABT, and AZN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/14/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.552.13%7/15/20248/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.11
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.73
0.89
0.70
Novartis AG stock logo
NVS
Novartis
0.43
0.90
0.71
Roche Holding AG stock logo
RHHBY
Roche
0.75
1.35
1.04

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Novartis AG stock logo
NVS
Novartis
13.12%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
1.10%
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Novartis AG stock logo
NVS
Novartis
0.01%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.72 billionOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
89,9003.10 billionN/AOptionable
Novartis AG stock logo
NVS
Novartis
76,0572.04 billion2.04 billionOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,605N/AN/ANot Optionable

RHHBY, NVS, ABT, and AZN Headlines

Recent News About These Companies

Roche Cancer Drug Gets Breakthrough Therapy Designation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Abbott Laboratories logo

Abbott Laboratories

NYSE:ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
AstraZeneca logo

AstraZeneca

NASDAQ:AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Novartis logo

Novartis

NYSE:NVS
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Roche logo

Roche

OTCMKTS:RHHBY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.